<PAGE>
ALLIANCE PHARMACEUTICAL CORP.
3040 SCIENCE PARK ROAD
SAN DIEGO, CA 92121
-------------
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
-------------
NOTICE IS HEREBY GIVEN that the Annual Meeting of Shareholders of
Alliance Pharmaceutical Corp. (the "Corporation") will be held at 10:00 a.m. on
Thursday, November 16, 1995, at the San Diego Marriott La Jolla, 4240 La Jolla
Village Drive, La Jolla, California 92037 for the following purposes:
1. To elect seven directors of the Corporation.
2. To approve an increase in the number of shares authorized for
issuance under the 1991 Stock Option Plan of Alliance
Pharmaceutical Corp. from 2,000,000 to 3,200,000.
3. To approve the amendment and restatement of the Formula Stock
Option Plan for Nonemployee Directors of the Corporation, as
described in the attached Proxy Statement.
4. To ratify the appointment by the Corporation's Board of Directors
of Ernst & Young LLP as independent auditors of the Corporation
for its fiscal year ending June 30, 1996.
5. To transact such other business as may properly come before the
annual meeting and any adjournments thereof.
Only holders of record of the Corporation's Common Stock and its Series A
Preferred Stock at the close of business on September 28, 1995, are entitled to
notice of, and to vote at, the meeting and any adjournments thereof. Such
shareholders may vote in person or by proxy. The stock transfer books of the
Corporation will not be closed.
Shareholders are urged to attend the meeting in person. If you are not
able to do so and wish that your shares be voted, please sign, date and return
the accompanying proxy in the enclosed envelope. No postage is required if
mailed in the United States.
By Order of the Board of Directors,
DUANE J. ROTH, Chairman
Dated: October 12, 1995
<PAGE>
ALLIANCE PHARMACEUTICAL CORP.
3040 SCIENCE PARK ROAD
SAN DIEGO, CA 92121
-----------
PROXY STATEMENT
ANNUAL MEETING OF SHAREHOLDERS
November 16, 1995
------------
GENERAL INFORMATION
This Proxy Statement is furnished in connection with the solicitation of
proxies by the Board of Directors of Alliance Pharmaceutical Corp. (the
"Corporation") to be voted at the Annual Meeting of Shareholders to be held on
Thursday, November 16, 1995, at 10:00 a.m. at the San Diego Marriott La Jolla,
4240 La Jolla Village Drive, La Jolla, California 92037 and at any adjournment
or adjournments thereof (the "Meeting") for the purposes set forth in the
accompanying Notice of Annual Meeting of Shareholders.
The mailing address of the principal executive offices of the Corporation
is 3040 Science Park Road, San Diego, CA 92121 (telephone number 619/558-4300).
The enclosed Proxy and this Proxy Statement are being first sent to shareholders
of the Corporation on or about October 12, 1995.
The Board of Directors has fixed the close of business on September 28,
1995 as the record date for the determination of shareholders of the Corporation
entitled to receive notice of, and vote at, the Meeting. At the close of
business on the record date, an aggregate of 24,850,735 shares of common stock,
par value $.01 per share, of the Corporation (the "Common Stock") were issued
and outstanding, each of which is entitled to one vote on each matter to be
voted upon at the Meeting, and 1,500,000 shares of Series A Preferred Stock, par
value $.01 per share, of the Corporation (the "Preferred Stock"), were issued
and outstanding, each of which is entitled to one-half vote on each matter to be
voted upon at the Meeting. The Common Stock and the Preferred Stock vote
together as one class.
All votes will be tabulated by the inspector of election appointed for the
Meeting, who will separately tabulate affirmative and negative votes,
abstentions and broker non-votes. Abstentions will be counted towards the
tabulation of votes cast on proposals presented to the shareholders and will
have the same effect as negative votes. Broker non-votes are not counted for
any purpose in determining whether a matter has been approved.
SOLICITATION AND REVOCATION
PROXIES IN THE FORM ENCLOSED ARE SOLICITED BY, OR ON BEHALF OF, THE BOARD
OF DIRECTORS OF THE CORPORATION. THE PERSONS NAMED IN THE PROXY HAVE BEEN
DESIGNATED AS PROXIES BY THE BOARD OF DIRECTORS. Shares represented by properly
executed proxies received by the Corporation will be voted at the Meeting in the
manner specified therein or, if no specification is made, will be voted FOR the
election of the seven directors listed herein, FOR an increase in the number of
shares authorized for issuance under the Corporation's 1991 Stock Option Plan,
FOR the amendment and restatement of the Formula Stock Option Plan For
Nonemployee Directors of the Corporation, and FOR the ratification of the
appointment by the Corporation's Board of Directors of Ernst & Young LLP as
independent auditors of the Corporation for its fiscal year ending June 30,
1996, all as described in this Proxy Statement.
Any proxy given by a shareholder pursuant to this solicitation may be
revoked by the shareholder at any time before it is exercised, by written
notification delivered to the Secretary of the Corporation, by voting in person
at the Meeting, or by executing another proxy bearing a later date.
<PAGE>
Proxies will be solicited by mail. They may also be solicited by officers
and regular employees of the Corporation personally, by telephone or otherwise,
but such persons will not be specifically compensated for such services. The
Corporation may use the services of Shareholder Communications Corporation to
aid in the solicitation of proxies. The Corporation estimates that the fee
payable to Shareholders Communications Corporation for such services should not
exceed $5,000. Banks, brokers, nominees and other custodians and fiduciaries
will be reimbursed for their reasonable out-of-pocket expenses in forwarding
soliciting material to their principals, the beneficial owners of Common Stock.
The costs of soliciting proxies will be borne by the Corporation.
1. ELECTION OF DIRECTORS
Seven directors are to be elected at the Meeting to hold office until the
next annual meeting of shareholders and until the election and qualification of
their respective successors. The Board of Directors has nominated Duane J.
Roth, Carroll O. Johnson, Stephen M. McGrath, Donald E. O'Neill, Helen M.
Ranney, M.D., Jean G. Riess, Ph.D., and Thomas F. Zuck, M.D., all of whom are
currently directors of the Corporation. Directors are elected by a plurality
vote.
Unless otherwise specified in the accompanying proxy, the shares voted
pursuant thereto will be cast for these nominees. If, for any reason, any of
the nominees should be unable to accept nomination or election, it is intended
that such proxy will be voted for the election, in his or her place, of a
substituted nominee who would be recommended by management. Management,
however, has no reason to believe that any nominee will be unable to serve as a
director.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOR OF EACH NAMED NOMINEE.
Set forth below is certain information with respect to each nominee as of
August 31, 1995:
DUANE J. ROTH. Mr. Roth is 45 and has served as a director of the
Corporation since 1985. He has served as President, Chief Operating Officer and
Chief Executive Officer of the Corporation since 1985 and has served as Chairman
since October 1989. Prior to joining the Corporation, Mr. Roth served as
President of Analytab Products, Inc., an American Home Products company involved
in manufacturing and marketing medical diagnostics, pharmaceuticals and devices.
For the previous ten years, he was employed in various sales, marketing and
general management capacities with Ortho Diagnostic Systems, Inc., a Johnson &
Johnson company, which is a manufacturer of diagnostic and pharmaceutical
products. Mr. Roth's brother, Theodore D. Roth, is an Executive Vice President
of the Corporation.
CARROLL O. JOHNSON. Mr. Johnson is 62 and has served as a director of the
Corporation since 1989. He has been President of Research Management, Inc.
("RMI") since 1985, an independent contract research organization which provides
services to the pharmaceutical industry in the implementation of clinical
trials. Previously, he served for 25 years in various research, sales and
marketing positions with several pharmaceutical companies, including Pharmacia
Laboratories, Inc., where he created a national sales force which introduced
three major products.
STEPHEN M. MCGRATH. Mr. McGrath is 59 and has served as a director of the
Corporation since 1989. He is an Executive Vice President of Oppenheimer & Co.,
Inc. ("Oppenheimer") and serves as the Director of its Corporate Finance
Department. For the eleven years prior to his employment by Oppenheimer in
1983, he held various executive positions with Warner-Lambert Company. Before
joining Warner-Lambert Company, Mr. McGrath was Controller and Assistant
Treasurer of Sterling Drug, Inc. and a certified public accountant for Price
Waterhouse & Co. He is a director of PetroCorp, Inc.
DONALD E. O'NEILL. Mr. O'Neill is 69 and has served as a director of the
Corporation since 1991. He retired from Warner-Lambert Company in 1991 after 20
years of service. During his tenure, he held various managerial positions,
including President of the Parke-Davis Group, President of the Health
Technologies Group and President - International Operations. At the time of his
retirement from Warner-Lambert Company, he held the offices of Executive Vice
President of the corporation and President and Chairman of its International
Operations. He is a
<PAGE>
director of New Jersey Resources Corporation, Targeted Genetics Corp., Scios-
Nova, Inc., MDL Information Systems, Inc., Immunogen, Inc. and Cytogen Corp.
HELEN M. RANNEY, M.D. Dr. Ranney is 75 and has served as a director of the
Corporation since 1991. She is Professor Emerita, Department of Medicine,
University of California at San Diego, having served as Chairman of the
Department from 1973 through 1986. From 1986 through 1991, she was
Distinguished Physician of the U.S. Department of Veterans Affairs. She
formerly was Professor of Medicine at Albert Einstein College of Medicine (New
York) and at the State University of New York, Buffalo. Dr. Ranney is a member
of many professional societies, including the National Academy of Sciences, the
Institute of Medicine, the Association of American Physicians (past President)
and the American Society of Hematology (past President). She has more than 150
publications, primarily relating to blood and blood disorders. Dr. Ranney
served on the Board of Directors of Squibb Corp. prior to its merger with
Bristol-Myers. She received her M.D. from the College of Physicians and
Surgeons, Columbia University.
JEAN G. RIESS, Ph.D. Professor Riess is 58 and has served as a director of
the Corporation since 1989. He has been the Director of Laboratoire de Chimie
Moleculaire at the University of Nice for over 20 years. He has been an active
researcher since receiving a Ph.D. from the University of Strasbourg, with
numerous patents and over 300 publications. For more than 20 years Dr. Riess
has focused on chemistry related to perfluorochemical emulsions for medical
application. In this field, his research group has been active in synthesis of
tailored perfluorochemicals, in emulsion technology, in synthesis of fluorinated
surfactants, in the physical chemistry of emulsion stabilization and in
surfactant self-aggregation. Dr. Riess is responsible for the Corporation's
research efforts at its affiliated company, Applications et Transferts de
Technologies Avancees in Nice, France.
THOMAS F. ZUCK, M.D. Dr. Zuck is 61 and has served as a director of the
Corporation since 1990. He is Professor of Transfusion Medicine and Director of
Hoxworth Blood Center at the University of Cincinnati Medical Center and is
President of Ohio Enterprises International, Inc. ("OEI"), a consulting company.
Dr. Zuck was formerly director of the Division of Blood and Blood Products at
the Office of Biologics Research & Review within the U.S. Food and Drug
Administration. He has served in numerous scientific professional societies,
including as President of the American Association of Blood Banks and the
Council of Community Blood Centers. He was Editor-in-Chief of the journal
Transfusion and has more than 100 publications to his credit. Dr. Zuck is a
retired U.S. Army Colonel, where he was a Commander of the Letterman Army
Institute of Research and, for many years, involved with the Army's blood
substitute development program. Dr. Zuck received his LL.B. from Yale Law
School and his M.D. from Hahnemann Medical College.
COMPENSATION OF DIRECTORS
Directors do not receive cash compensation for attendance at Board of
Directors' meetings or committee meetings. Non-qualified stock options are
awarded to nonemployee directors of the Corporation pursuant to the Formula
Stock Option Plan for Nonemployee Directors of the Corporation (the "Directors'
Formula Option Plan"). Options under the Directors' Formula Option Plan are
granted under and subject to the Corporation's 1991 Stock Option Plan. The
options have a term of ten years from the date of grant and are exercisable at a
price per share equal to the fair market value of a share of Common Stock on the
date of grant. The present formula for awarding the options is as follows:
each person who was a nonemployee director of the Corporation in November 1992,
and served as a director for two or more years, upon each annual meeting of the
Board of Directors of the Corporation (the "Annual Meeting") that such person
remains a nonemployee director, shall automatically be granted an option to
acquire 3,500 shares of Common Stock; each person who was a nonemployee director
of the Corporation and served as a director for less than two years in November
1992, upon the fourth Annual Meeting following his or her initial election and
each Annual Meeting thereafter that such person remains a nonemployee director,
shall automatically be granted an option to acquire 3,500 shares of Common
Stock; and each person who first becomes a nonemployee director of the
Corporation after November 1992; (i) upon his or her initial election, shall
automatically be granted an option to acquire 25,000 shares of Common Stock
which shall be exercisable in four installments of 6,250 shares each with the
first installment being at his or her initial election and the remaining
installments becoming exercisable on the date of each Annual Meeting thereafter
that such person is a director, until fully exercisable, and (ii) upon the
fourth Annual Meeting following his or her initial election and each Annual
Meeting thereafter that such person remains a
<PAGE>
nonemployee director, shall automatically be granted an option to acquire 3,500
shares of Common Stock. Except as otherwise described above, all options are
immediately exercisable in full on the date of grant. The shareholders are being
asked to amend and restate the Directors' Formula Option Plan at the Meeting to
increase the number of shares under each annual option grant to nonemployee
directors. See Proposal 3, page 14.
OTHER TRANSACTIONS
The following affiliations exist between the Corporation and certain
directors:
Mr. McGrath is an Executive Vice President of Oppenheimer, an investment
banking firm which renders financial advice to the Corporation from time to
time. In April 1995, the Corporation completed public offerings of newly issued
Common Stock in which Oppenheimer participated as a placement agent. The
Corporation has also retained Oppenheimer to provide financial advice in
connection with future collaborative agreements for certain of the Corporation's
products. Additionally, in September 1995, the Board of Directors voted to
extend the maturity dates of certain warrants for Common Stock initially issued
to Oppenheimer by two years in consideration of financial services provided by
Oppenheimer. Mr. McGrath abstained from voting on such extension. Some of the
warrants have been transferred by Oppenheimer to various Oppenheimer employees
and, using the Black Scholes valuation model, the Corporation estimates that the
value of the term extension for the warrants held by Mr. McGrath is
approximately $18,600.
In October 1994, the Corporation renewed a one-year research services
agreement with RMI for $2,000 per month. Mr. Johnson is the president and owner
of RMI.
Dr. Zuck received $2,000 per month through December 1994 for providing
consulting services to the Corporation. In January 1995, the Corporation
entered into a one-year consulting agreement with OEI for $2,000 per month. Dr.
Zuck is the president and owner of OEI.
Dr. Ranney receives $2,000 per month for providing consulting services to
the Corporation.
COMMITTEES OF THE BOARD OF DIRECTORS AND MEETING ATTENDANCE
The standing committees of the Board of Directors consist of an Executive
Committee, a Compensation Committee, a Nominating Committee, an Audit Committee
and a Stock Option Committee. The Executive Committee was established to act
when the full Board of Directors is unavailable. It has all the authority of
the Board between meetings of the entire Board as to matters which have not been
specifically delegated to other committees of the Board, except the authority
that by law cannot be delegated by the Board of Directors. The members of the
Executive Committee are Mr. Roth and Drs. Ranney and Zuck. The Compensation
Committee advises and makes recommendations to the Board of Directors regarding
matters relating to the compensation of directors, officers and senior
management. The members of the Compensation Committee are Dr. Ranney and
Messrs. McGrath and O'Neill. The Audit Committee advises and makes
recommendations to the Board concerning the internal controls of the Corporation
and the independent auditors to be nominated for election by the shareholders
and other matters relating to the financial activities of the Corporation. The
members of the Audit Committee are Messrs. Johnson, McGrath and O'Neill. The
Nominating Committee has the authority to nominate members of the Board of
Directors to the entire Board for consideration. The Nominating Committee will
not consider nominees recommended by shareholders. The members of the
Nominating Committee are Dr. Riess and Messrs. Johnson and Roth. The Stock
Option Committee has the authority to administer the Corporation's stock option
plans. The members of the Stock Option Committee are Dr. Zuck and Messrs.
Johnson and McGrath.
During the fiscal year ended June 30, 1995, there were five meetings of the
Board of Directors. The Stock Option Committee held four meetings, the
Compensation Committee held two meetings, the Audit Committee held two meetings,
the Nominating Committee held one meeting, and the Executive Committee did not
meet. Each Board member attended all of the meetings of the Board and all of
the meetings of the committee(s) of which he or she is a member.
<PAGE>
COMPLIANCE WITH SECTION 16(a) OF THE SECURITIES EXCHANGE ACT OF 1934
Section 16(a) of the Securities Exchange Act of 1934 requires the
Corporation's directors and executive officers, and persons who own more than
10% of a registered class of the Corporation's equity securities, to file with
the Securities and Exchange Commission ("SEC") initial reports of ownership and
reports of changes in ownership of Common Stock and other equity securities of
the Corporation. Officers, directors and greater than 10% stockholders are
required by SEC regulations to furnish the Corporation with copies of all
Section 16(a) forms they file.
To the Corporation's knowledge, based solely on a review of the copies of
such reports furnished to the Corporation during the fiscal year ended June 30,
1995, one report, covering one transaction, was filed late on behalf of Dr.
Ranney.
OWNERSHIP OF VOTING SECURITIES BY CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information with respect to the
beneficial ownership of the Corporation's voting securities as of August 31,
1995 as to (i) each of the directors and director nominees, (ii) each of the
executive officers listed in the Summary Compensation Table, (iii) each person
known by the Corporation to own more than 5% of any class of the Corporation's
outstanding voting securities, and (iv) all directors and executive officers of
the Corporation as a group.
<TABLE>
<CAPTION>
Amount and Nature of Percentage of
Name and Address Beneficial Ownership (1) Class (2)
- - ---------------- ------------------------- -------------
<S> <C> <C>
Common Stock
------------
Duane J. Roth 388,856 (3) 1.6%
Carroll O. Johnson 23,000 (4) *
Stephen M. McGrath 63,826 (5) *
Donald E. O'Neill 38,500 (6) *
Helen M. Ranney, M.D. 29,800 (7) *
Jean G. Riess, Ph.D. 91,233 (8) *
Thomas F. Zuck, M.D. 40,500 (9) *
Harold W. DeLong 95,950 (10) *
Theodore D. Roth 105,517 (11) *
N. Simon Faithfull, M.D., Ph.D. 59,450 (12) *
Ronald M. Hopkins, Ph.D. 70,512 (13) *
All directors and executive 1,197,379 4.7%
officers as a group (14 persons)
Long Family Trusts 1,779,715 (14) 7.2%
10988 Horizon Hills Drive
El Cajon, CA 92020
Wellington Management Company 2,845,888 (15) 11.5%
75 State Street
Boston, MA 02109
Series A Preferred Stock
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C>
Johnson & Johnson Development 1,500,000 (16) 100%
Corporation
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
- - --------------------------------------------------------------------------------------------------------------------
</TABLE>
* Indicates ownership of less than 1% of outstanding shares.
(1) Each person listed or included in the group has sole voting power and sole
investment power with respect to the shares owned by such person, except as
indicated below.
(2) Shares subject to options and warrants exercisable within 60 days have been
deemed to be outstanding for percentage calculations with respect to the
person holding such options and warrants.
(3) Consists of (i) 214,000 shares owned by Mr. Roth, (ii) 93,800 shares
subject to options granted by the Corporation under its 1983 Non-Qualified
Stock Option Program ("the 1983 Program"), (iii) 80,200 shares subject to
options granted by the Corporation under its 1991 Stock Option Plan ("the
1991 Plan"), and (iv) 856 shares owned by Mr. Roth's spouse.
(4) Consists of (i) 5,000 shares owned by Mr. Johnson and (ii) 18,000 shares
subject to options granted by the Corporation under the 1991 Plan.
(5) Consists of (i) 38,000 shares owned by Mr. McGrath, (ii) 15,326 shares
subject to warrants, and (iii) 10,500 shares subject to options granted by
the Corporation under the 1991 Plan.
(6) Consists of (i) 8,000 shares owned by Mr. O'Neill, (ii) 28,500 shares
subject to options granted by the Corporation under the 1991 Plan, and
(iii) 2,000 shares owned by Mr. O'Neill's spouse.
(7) Consists of (i) 1,300 shares owned by Dr. Ranney and (ii) 28,500 shares
subject to options granted by the Corporation under the 1991 Plan.
(8) Consists of (i) 80,733 shares owned by Dr. Riess and (ii) 10,500 shares
subject to options granted by the Corporation under the 1991 Plan.
(9) Consists of (i) 30,000 shares subject to options granted by the Corporation
under the 1983 Program and (ii) 10,500 shares subject to options granted by
the Corporation under the 1991 Plan.
(10) Consists of (i) 22,000 shares owned by Mr. DeLong, (ii) 8,600 shares
subject to options granted by the Corporation under the 1983 Program, and
(iii) 65,350 shares subject to options granted by the Corporation under the
1991 Plan.
(11) Consists of (i) 20,500 shares owned by Mr. Roth, (ii) 19,667 shares subject
to options granted by the Corporation under the 1983 Program, and (iii)
65,350 shares subject to options granted by the Corporation under the 1991
Plan.
(12) Consists of (i) 7,000 shares owned by Dr. Faithfull, (ii) 43,000 shares
subject to options granted by the Corporation under the 1983 Program and
(iii) 9,450 shares subject to options granted by the Corporation under the
1991 Plan.
(13) Consists of (i) 297 shares owned by Dr. Hopkins' spouse, (ii) 45,000 shares
subject to options granted by the Corporation under the 1983 Program, (iii)
9,450 shares subject to options granted by the Corporation under the 1991
Plan, and (iv) 15,765 shares subject to options granted by the Corporation
to Dr. Hopkins' spouse under the 1991 Plan.
(14) Consists of (i) 1,620,285 shares owned by The Long Family Trust, (ii) 8,430
shares owned by The Long Family Charitable Remainder Unitrust, (iii) 33,500
shares owned by The David M. Long, Jr. and Donna R. Long Irrevocable Trust,
and (iv) 112,500 shares owned by The David M. Long, Jr. and Donna R. Long
Second Unitrust, and (v) 5,000 shares owned by David M. Long, Jr. Both
David M. Long, Jr. and Donna R. Long are co-trustees of the various trusts
and may be deemed to be beneficial owners of such shares. Donna R. Long
disclaims beneficial ownership of 5,000 shares owned directly by her
husband, David M. Long, Jr. Does not include 215,650 shares owned by D.
Carl Long or 19,100 shares owned by Raymond A. Long.
(15) Wellington Management Company ("WMC") in its capacity as investment advisor
may be deemed beneficial owner of these shares which are owned by many
clients. WMC has shared voting power over 1,207,000 shares and shared
dispositive power over all such shares.
(16) The Series A Preferred Stock ("Preferred Stock") has one-half vote per
share and votes together with the Common Stock as one class, except where
otherwise required by law. The Corporation sold the Preferred Stock to
Johnson & Johnson Development Corporation ("J&JDC") and issued to J&JDC a
warrant to purchase 300,000 shares of the Corporation's Common Stock.
These
<PAGE>
transactions occurred in conjunction with the Corporation's grant, in
August 1994, to Ortho Biotech, Inc. and The R.W. Johnson Pharmaceutical
Research Institute, a division of Ortho Pharmaceutical Corporation
(collectively referred to as "Ortho"), of a worldwide license agreement
("License Agreement") for injectable PFC emulsions capable of transporting
oxygen for therapeutic use. Ortho is an affiliate of J&JDC. The Preferred
Stock is convertible into Common Stock upon certain events at a rate based
upon a 20-day average of the fair market value of the Common Stock at
conversion. In addition, Ortho agreed to pay certain licensing and
milestone fees, to pay for the remaining development expenses for the
product on a worldwide basis, and to pay royalties to the Corporation after
commercialization.
EXECUTIVE COMPENSATION
The following table sets forth information concerning annual and long-term
compensation for the Corporation's Chief Executive Officer and the other four
highest paid executive officers (collectively, the "Named Executive Officers")
for the year ended June 30, 1995, as well as the total compensation paid to each
individual for the Corporation's two previous fiscal years:
<TABLE>
<CAPTION>
Summary Compensation Table
Long-Term
Compen-
Annual Compensation sation
-----------
Awards
------------------------------------- -----------
Name Other Securities
and Annual Underlying
Principal Salary Bonus Compen- Options/
Position Year ($) ($) sation ($) (a) SARs (#)
- - ----------------------------------------------- ---- ------ ------ --------------- ----------
<S> <C> <C> <C> <C> <C>
Duane J. Roth 1995 309,200 - - 132,500
Chairman of the Board, President, Chief 1994 291,000 89,000 - 50,000
Executive Officer, Chief Operating Officer 1993 260,000 68,000 67,000 (b) 30,900
Harold W. DeLong 1995 169,700 - - 40,000
Executive Vice President - Business 1994 161,700 30,375 - 15,000
Development and Marketing 1993 148,500 22,000 - 19,500
Theodore D. Roth 1995 171,300 - 69,600 (c) 40,000
Executive Vice President, Secretary, 1994 161,700 30,375 - 15,000
Chief Financial Officer 1993 148,500 22,000 - 19,500
N. Simon Faithfull 1995 174,500 - - 32,000
Vice President - Medical Research 1994 167,100 22,500 - 10,000
1993 160,000 17,000 - 5,250
Ronald M. Hopkins 1995 161,500 - - 32,000
Vice President - Research and Development 1994 153,000 22,500 - 10,000
1993 140,000 17,000 - 5,250
- - ----------------------------------------------------------------------------------------------------
</TABLE>
(a) Perquisites and other personal benefits for specific officers are only
reported in specific years where such compensation exceeds the lower of 10%
of annual salary and bonus, or $50,000.
(b) Includes relocation expense and tax reimbursement of $51,000.
(c) Includes forgiveness of $57,065 of principal and accrued interest on a
relocation loan.
<PAGE>
EMPLOYMENT ARRANGEMENTS
On October 20, 1994, in connection with the exercise of certain stock
options previously granted to Duane Roth, the Corporation loaned Mr. Roth
$196,330 in accordance with the terms of the 1983 Program. Interest is due and
payable quarterly and all outstanding principal is due and payable on October
20, 1999. Interest accrues at the rate of seven and three-quarters percent per
annum. The note is secured by the 29,000 shares of Common Stock of the
Corporation obtained by Mr. Roth upon exercise of the stock options.
During fiscal 1992, in connection with his relocation, the Corporation
loaned Theodore Roth $175,000, which was originally due on August 5, 1994. The
loan bears interest at the prime rate reported in The Wall Street Journal and
had an outstanding principal balance of $150,000 as of that date. The loan is
evidenced by a promissory note secured by real estate and an assignment of Mr.
Roth's option to purchase stock of the Corporation. On February 16, 1994, the
Board of Directors authorized the Corporation to forgive on December 1, 1994 and
each December 1 thereafter, through December 1, 1998, $30,000 of principal and
all accrued interest through such date; provided Mr. Roth remains employed by
the Corporation. If his termination is without cause by the Corporation or as a
result of a change in control of the Corporation, the debt will be forgiven in
full. Termination of his employment for any other reason requires the debt to
be paid three years from the termination date, with interest.
On June 1, 1995, the Corporation loaned Simon Faithfull $70,000. The loan
accrues interest at the rate of nine percent per annum. The loan is due and
payable on demand; provided that unless and until demand is made, principal and
interest shall be payable in biweekly installments of $500 each. The note is
secured by a lien on Dr. Faithfull's primary residence.
STOCK OPTION GRANTS AND EXERCISES
The Corporation has granted options to its executive officers under its
1983 Incentive Stock Option Plan (which plan expired on October 1, 1993), its
1983 Non-Qualified Stock Option Program and its 1991 Stock Option Plan. No
stock appreciation rights ("SARs") have been granted by the Corporation. The
following table sets forth certain information concerning options granted during
fiscal 1995 to the Named Executive Officers:
<TABLE>
<CAPTION>
Option/SAR Grants in Last Fiscal Year
Potential Realizable Value at Assumed
Annual Rates of
Individual Grants Stock Price Appreciation for
Option Term (1)
------------------------------------------------------- ---------------------------------------
Securities % of Total
Underlying Options/SARs
Options/ Granted to Exercise or
SARs Employees in Base Price Expiration
Name Granted (#) (2) Fiscal Year ($/Share) (4) Date 5% ($) 10% ($)
- - ---- ------------ ------------- -------------- ---------- ----------- -----------
<S> <C> <C> <C> <C> <C> <C>
Duane J. Roth 132,500 (3) 10.6% 5.25 05/16/05 370,000 1,001,200
Harold W. DeLong 40,000 (3) 3.2% 5.25 05/16/05 111,700 302,300
Theodore D. Roth 40,000 (3) 3.2% 5.25 05/16/05 111,700 302,300
N. Simon Faithfull 32,000 (3) 2.6% 5.25 05/16/05 89,400 241,800
Ronald M. Hopkins 32,000 (3) 2.6% 5.25 05/16/05 89,400 241,800
- - ----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
(1) The dollar amounts under these columns are the result of calculations
assuming that the price of Common Stock on the date of the grants of the
options ($5.25 per share) increases at the hypothetical 5% and 10% rates set
by the Securities and Exchange Commission and therefore are not intended to
forecast possible future appreciation, if any, of the Corporation's stock
price.
(2) All options granted in 1995 to the Named Executive Officers were non-
qualified stock options under the 1991 Plan.
(3) Options are exercisable in increments of 20% commencing on the date of
issuance and on each subsequent anniversary.
(4) The exercise price per share of the options granted represented the fair
market value of the underlying shares on the date of grant. Options must be
exercised by paying the Corporation at least the par value of the shares of
Common Stock being acquired, allowing the remainder of the exercise price to
be borrowed from the Corporation. The 1991 Plan provides that such loans
shall mature within five years (or earlier, in the event of a termination of
employment or of a consultancy), shall be secured by the shares of Common
Stock purchased, shall provide for quarterly payments of interest at such
rate as the Board of Directors may determine and shall be in such form and
contain such other provisions as the Board of Directors may determine from
time to time.
The following table summarizes options exercised during fiscal 1995 and
presents the value of unexercised options held by the Named Executive Officers
at fiscal year end:
Aggregated Option/SAR Exercises in Last Fiscal Year and Fiscal Year-End
Option/SAR Values
<TABLE>
<CAPTION>
Number of Value of
Securities Unexercised
Underlying In-the-Money
Unexercised Optons/SARs
Options/SARs At Fiscal
Shares at Fiscal Year End (#) Year End($)
Acquired on Value Exercisable (E)/ Exercisable (E)/
Exercise (#) Realized($) Unexercisable (U) Unexercisable (U)
----------- ----------- --------------------- -----------------
<S> <C> <C> <C> <C>
Duane J. Roth 29,000 20,900 174,000 E 689,000 E
163,200 U 318,000 U
Harold W. DeLong 0 0 73,950 E 94,900 E
49,150 U 96,000 U
Theodore D. Roth 0 0 85,017 E 186,100 E
49,150 U 96,000 U
N. Simon Faithfull 7,000 30,000 52,450 E 234,200 E
37,800 U 76,800 U
Ronald M. Hopkins 0 0 54,450 E 143,000 E
37,800 U 76,800 U
- - -------------------------------------------------------------------------------------------------
</TABLE>
COMPENSATION COMMITTEE
REPORT
The Compensation Committee of the Board of Directors (the "Committee") has
provided the following report:
The Committee is composed entirely of outside, nonemployee directors. The
Committee determines the base salaries and the amount of bonus awards to be paid
to the executive officers of the Corporation. In addition, the Committee
recommends the number of the Corporation's stock option grants which should be
made to executive officers and other employees of the Corporation. The
following is a summary of policies of the Committee that affect the compensation
paid to executive officers, as reflected in the tables and text set forth
elsewhere in the proxy statement.
Executive Compensation Policy and Components of Compensation
- - ------------------------------------------------------------
<PAGE>
The Committee's fundamental executive compensation philosophy is to enable
the Corporation to attract and retain key executive personnel and to motivate
those executives to achieve the Corporation's objectives. The Corporation is
still in its research and development phase and has not yet achieved
profitability. Therefore, traditional methods of evaluating executive
performance, such as sales and profit levels, return on equity, and stock price,
are inappropriate. Accordingly, assessment of each executive's performance is
based upon attainment of his or her specific objectives in relation to the
Corporation's overall annual strategic goals. The Committee may in its
discretion apply different measures of performance for future fiscal years.
However, it is presently contemplated that all compensation decisions will be
designed to further the fundamental executive compensation philosophy described
above.
Each executive officer's compensation package is reviewed annually and is
comprised of three components: base salary, bonus, and stock option grants. In
addition, executive officers of the Corporation are eligible to participate in
all benefit programs generally available to other employees.
Base Salary
- - -----------
In setting the base salary levels of each executive officer, the Committee
considers the base salaries of executive officers in comparable positions in
other similarly situated biotechnology/pharmaceutical development companies. In
setting levels, the Corporation currently targets the 75th percentile of the
relevant labor market. Factors considered include company size, stage of
development of a company's products, and geographical location. The Committee
also considers the individual experience level and actual performance of each
executive officer in view of the Corporation's needs and objectives. Salary
decisions are determined in a structured annual review by the Committee with
input from the Chief Executive Officer.
Bonus Awards
- - ------------
Annual bonuses, set as a targeted percentage of total cash compensation,
may be earned by each executive officer, based upon the achievement of
performance goals established at the beginning of the fiscal year and reviewed
at least twice during the year.
Performance goals for the Corporation are developed by management, and
reviewed and approved by the Committee and the Board of Directors. Performance
goals for individual executives are developed by the Chief Executive Officer,
and reviewed and approved by the Committee. Bonuses are awarded to executives
based upon the attainment of these goals during the year, with the Corporation
and the executives accomplishing minimum objectives prior to being eligible to
receive a bonus. The Committee considers the amounts of bonuses it expects to
pay to executives when it compares its compensation practices with other
companies similarly situated.
Long-Term Stock-Based Incentive Compensation
- - --------------------------------------------
Generally, the Corporation's stock option committee approves annual grants
of stock options to each of the Corporation's executive officers under the 1991
Plan based upon recommendations from the Committee. The grants are designed to
align the interest of each executive officer with those of the shareholders and
provide each individual with a significant incentive to manage the Corporation
from the perspective of an owner with an equity stake in the business. Each
grant generally allows the officer to acquire shares of the Corporation's Common
Stock at a fixed price per share (the market price on the grant date) over a
specified period of time (up to ten years), thus providing a return to the
executive officer only if the market price of the shares appreciates over the
option term. The size of the option grant to each executive officer generally
is set as the Committee deems appropriate in order to retain and motivate key
executive officers as well as to provide them with the perspective of the
Corporation's shareholders in assessing corporate results. The grants also take
into account comparable awards to individuals in similar positions at
biotechnology/pharmaceutical development companies as reflected in external
surveys, the individual's potential for future responsibility and promotion over
the option term, the individual's personal performance in recent periods, and
the risk attached to the future growth of the pharmaceutical industry. In
making comparisons in the industry, the Corporation targets the 75th percentile
of the relevant labor market.
<PAGE>
The Committee, at its discretion, has the authority to utilize compensation
consultants to assist in defining the relevant labor market for executive
compensation and to recommend annual salary and bonus increases.
Duane J. Roth, Chief Executive Officer, although not a member of the
Committee, assisted the Committee in developing the compensation packages
awarded to executive officers other than himself.
CEO Compensation
- - ----------------
In setting the compensation payable to the Corporation's Chief Executive
Officer, the Committee sought to be competitive with other
biotechnology/pharmaceutical development companies. In making comparisons, the
Corporation targets the 75th percentile of the relevant labor market. The
Committee established Duane Roth's base salary based on an evaluation of his
personal performance and the objective of having his base salary keep pace with
salaries being paid to similarly situated chief executive officers. With
respect to his base salary, it is the Committee's intent to provide him with a
level of stability and certainty each year and not have this particular
component of compensation affected to any significant degree by Corporation
performance factors. The remaining component of his 1995 fiscal year
compensation, however, was dependent upon performance and provided no dollar
guarantees.
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
No member of the Compensation Committee is a former or current officer or
employee of the Corporation or any of its subsidiaries.
COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS
Donald E. O'Neill, Chairman Dr. Helen M. Ranney
Stephen M. McGrath
Mr. McGrath is an Executive Vice President of Oppenheimer, an investment
banking firm which renders financial advice to the Corporation from time to
time. In April 1995, the Corporation completed public offerings of newly issued
Common Stock in which Oppenheimer participated as a placement agent. The
Corporation has also retained Oppenheimer to provide financial advice in
connection with future collaborative agreements for certain of the Corporation's
products. Additionally, in September 1995, the Board of Directors voted to
extend the maturity dates of certain warrants for Common Stock initially issued
to Oppenheimer by two years in consideration of financial services provided by
Oppenheimer. Mr. McGrath abstained from voting on such extension. Some of the
warrants have been transferred by Oppenheimer to various Oppenheimer employees
and, using the Black Scholes valuation model, the Corporation estimates that the
value of the term extension for the warrants held by Mr. McGrath is
approximately $18,600.
STOCK PERFORMANCE GRAPH
The following graph compares the cumulative total shareholder return to the
Corporation's shareholders during the five-year period ended June 30, 1995, as
well as with that of an overall stock market index (NASDAQ) and a published
industry index (NASDAQ Pharmaceutical Stocks):
[GRAPH APPEARS HERE]
<TABLE>
COMPARISON OF FIVE YEAR CUMULATIVE RETURN
AMONG ALLP, NASDAQ (US) AND NASDAQ PHARM
<CAPTION>
Measurement period
(Fiscal year Covered) ALLP NASDAQ (US) NASDAQ PHARM
- - --------------------- ---- ----------- ------------
<S> <C> <C> <C>
Measurement PT -
06/30/90 $ 100 $ 100 $ 100
FYE 06/30/91 $ 96.77419 $105.8855 $159.6582
FYE 06/30/92 $161.2903 $127.2042 $198.7864
FYE 06/30/93 $ 76.34409 $159.9692 $172.8032
FYE 06/30/94 $ 83.87097 $161.5612 $144.5531
FYE 06/30/95 $ 70.96774 $215.3633 $193.6003
</TABLE>
<PAGE>
[GRAPH APPEARS HERE]
2. PROPOSED AMENDMENT OF THE 1991 STOCK OPTION PLAN
Effective November 8, 1991, the Board of Directors and the shareholders of
the Corporation adopted the 1991 Non-Qualified Stock Option Program (the "1991
Program") pursuant to which 1,000,000 shares of Common Stock were reserved for
issuance upon the exercise of options granted under the terms of the 1991
Program. On November 19, 1994, the shareholders of the Corporation approved the
amendment and restatement of the 1991 Program (as amended and restated, it is
entitled the 1991 Stock Option Plan of Alliance Pharmaceutical Corp., the "1991
Plan") pursuant to which an additional 1,000,000 shares of Common Stock were
reserved for issuance upon the exercise of options granted under the terms of
the 1991 Plan. As of August 31, 1995, only 66,530 shares remained available for
issuance under the 1991 Plan. On September 1, 1995, the Board of Directors
approved an amendment to the 1991 Plan, subject to shareholder approval, to
increase the number of shares authorized for issuance under the 1991 Plan from
2,000,000 to 3,200,000 shares.
The Board believes that the increase is necessary to meet the Corporation's
objectives of motivating and retaining officers, employees, and nonemployee
consultants with appropriate experience and ability, and to increase the
grantees' alignment of interest with the Corporation's shareholders. The
increase of 1,200,000 shares represents 4.2 percent of the Corporation's Common
Stock on a fully diluted basis as of June 30, 1995.
DESCRIPTION OF THE PLAN
The following is a summary of the principal features of the 1991 Plan:
PURPOSE
The purpose of the 1991 Plan is to assist the Corporation in the
recruitment, retention and motivation of directors, officers, employees and
consultants who are providing, or who are expected to provide, services which
are
<PAGE>
deemed important to the Corporation, by enabling them to acquire the
Corporation's Common Stock, thereby increasing their proprietary interest in and
commitment to the growth and success of the Corporation.
ADMINISTRATION
The 1991 Plan is administered by the Stock Option Committee of the Board of
Directors. The members of the Stock Option Committee are appointed by, and
serve at the pleasure of, the Board of Directors. The Stock Option Committee,
which will be referred to in this summary as the Plan Administrator, has full
authority, subject to the provisions of the 1991 Plan, to determine the eligible
individuals who are to receive option grants under the 1991 Plan, the type of
option (incentive stock option or non-qualified stock option) to be granted, the
consideration for the granting of such options, the number of shares to be
covered by each granted option, the date or dates on which the option is to
become exercisable, and the maximum term for which the option is to remain
outstanding.
The Board members who serve as the Plan Administrator may not, either
during the one-year period prior to their appointment as Plan Administrator or
during their period of service as such, receive any stock options under the 1991
Plan or any other stock plan of the Corporation or its subsidiaries, except in
accordance with the shareholder approved Directors' Formula Option Plan.
ELIGIBILITY AND SHARES SUBJECT TO THE 1991 PLAN
Under the 1991 Plan, 3,200,000 shares of Common Stock have been reserved
for issuance (1,200,000 shares of which are subject to shareholder approval at
the Meeting) upon the exercise of options granted pursuant to the terms of the
1991 Plan. The 1991 Plan provides for the grant of both incentive stock options
("ISOs") intended to qualify as such under section 422 of the Internal Revenue
Code of 1986, as amended, and non-qualified stock options ("NSOs"). ISOs may be
granted only to employees of the Corporation. NSOs may be granted to employees,
nonemployee directors and consultants who provide services which are deemed
important to the Corporation. If any options granted under the 1991 Plan shall
for any reason expire or be canceled or otherwise terminated without having been
exercised in full, the shares allocable to the unexercised portion of such
options shall again become available for the 1991 Plan. If options issued under
the 1991 Plan are canceled unexercised, they also become available for new
grants. Options to purchase more than 200,000 shares may not be granted to any
individual in a single calendar year under the 1991 Plan.
As of June 30, 1995, options to purchase an aggregate of 3,043,988 shares
of Common Stock, at a weighted average exercise price of $9.02 per share, were
outstanding under all of the Corporation's stock option plans (including options
granted under the 1983 Incentive Stock Option Plan, which plan expired on
October 1, 1993). As of June 30, 1995, approximately 190 employees (including
one director who is an employee) and six nonemployee directors were eligible to
participate in the 1991 Plan. On August 31, 1995, the closing price for the
Corporation's Common Stock on the NASDAQ National Market was $8.50. All stock
options granted since November 15, 1991 have been granted with exercise prices
equal to the closing price for the Company's Common Stock on the NASDAQ National
Market on the date of grant. As of June 30, 1995, 1,731,575 stock options
granted under all of the stock option plans had been exercised, and stock
options for a total of 1,289,725 shares of Common Stock are available for future
grants (including those available under the amendment to the 1991 Plan to be
approved at the Meeting).
As of August 31, 1995, the following persons or groups had, in total,
received options to purchase shares of Common Stock under the 1991 Plan as
follows: (i) the Chief Executive Officer and the other Named Executive Officers:
Duane J. Roth, Chairman and Chief Executive Officer, 243,400 shares; Harold W.
DeLong, Executive Vice President - Business Development and Marketing, 114,500
shares; Theodore D. Roth, Executive Vice President, 114,500 shares; N. Simon
Faithfull, Vice President - Medical Research, 47,250 shares; Ronald M. Hopkins,
Vice President - Research and Development, 47,250 shares; (ii) all current
executive officers of the Corporation as a group: 738,050 shares; (iii) all
current directors who are not executive officers as a group: 106,500 shares;
(iv) each nominee for election as a director (including options granted pursuant
to the Directors' Formula Option Plan described below): Carroll O. Johnson
18,000, Stephen M. McGrath 10,500, Donald E. O'Neill 28,500, Helen M. Ranney
28,500, Jean G. Riess 10,500, and Thomas F. Zuck 10,500; (v) each person who has
received 5% of options granted other than those named above: no shares; (vi) all
employees of the Corporation, including all current officers who are not
<PAGE>
executive officers, as a group: 1,211,250 shares; and (vii) each associate of
any such directors, executive officers, or nominees: Carol Hopkins (Ronald
Hopkins' wife), 37,300 shares.
TERMS OF OPTIONS
Each option granted under the 1991 Plan must be exercised within ten years
of the date of its grant unless the Plan Administrator specifies some lesser
time. Stock options granted under the 1991 Plan must be exercised by the
optionee before the earlier of the expiration of such option or the date ten
days after termination of the optionee's employment or service, except that this
period is extended to three months in the case of the optionee's retirement at
or after age 65 or termination of employment or service due to disability, and
to six months in the case of the optionee's death, in which case the option is
exercisable by the optionee's estate. Options granted pursuant to the 1991
Plan, except for grants to nonemployee directors (which vest in accordance with
the Nonemployee Director Formula Plan), will vest at the time or times
determined by the Plan Administrator. Options become immediately exercisable in
full upon the optionee's retirement at or after age 65 or termination of
employment or service due to disability or death, or upon the occurrence of such
circumstance or event as in the opinion of the Plan Administrator merits special
consideration.
Options are subject to such terms and conditions, including price and rate
of exercise, as the Plan Administrator may determine. However, the exercise
price for ISOs will be no less than 100% of fair market value on the date of
grant. The exercise price for NSOs will be no less than either the par value of
said shares ($.01 per share) or eighty percent (80%) of the fair market value of
said shares on the date of grant.
Payment of the purchase price for shares purchased pursuant to the exercise
of an option may be made by cash or check, by a "cashless" exercise method
through a broker, or by such other methods as the Plan Administrator may permit
from time to time. A grantee who is an employee of or a consultant to the
Corporation at the time of exercise of an option may, if authorized by the Plan
Administrator, exercise his/her option by paying the Corporation at least the
par value of the shares of Common Stock being acquired and borrowing the
remainder of the exercise price from the Corporation. The 1991 Plan provides
that such loans shall mature within five years (or earlier, in the event of a
termination of employment or of a consultancy), shall be secured by the shares
of Common Stock purchased, shall provide for quarterly payments of interest at
such rate as the Plan Administrator may determine and shall be in such form and
contain such other provisions as the Plan Administrator may determine from time
to time.
DURATION, AMENDMENT AND TERMINATION
The 1991 Plan expires on November 7, 2001. The 1991 Plan may be amended,
suspended or terminated at any time by action of the Board of Directors or the
Plan Administrator, except that no such action may, without shareholder
approval, increase the maximum number of shares reserved for options under the
1991 Plan or for any individual, change the class of eligible persons or
materially increase the benefits accruing to eligible persons under the 1991
Plan. Furthermore, no action may, without the consent of an optionee, adversely
affect his/her rights under any option theretofore granted.
FEDERAL INCOME TAX CONSEQUENCES
Neither the optionee nor the Corporation will incur any federal tax
consequences as a result of the grant of an option. The optionee will have no
taxable income upon exercising an ISO (except that the alternative minimum tax
may apply), and the Corporation will receive no deduction when an ISO is
exercised. Upon exercising an NSO, the optionee generally must recognize
ordinary income equal to the "spread" between the exercise price and the fair
market value of the Common Stock on the date of exercise; and the Corporation
will be entitled to a deduction for the same amount. In the case of an
employee, the option spread at the time an NSO is exercised is subject to income
tax withholding. The tax treatment of a disposition of option shares acquired
under the 1991 Plan depends on how long the shares have been held and on whether
such shares were acquired by exercising an ISO or NSO. The Corporation will not
be entitled to a deduction in connection with a disposition of option shares,
except in the case of a disposition of shares acquired under an ISO before the
applicable ISO holding periods have been satisfied.
<PAGE>
Shareholders are requested in this Proposal 2 to approve the increase in
the number of shares authorized for issuance under the 1991 Plan from 2,000,000
to 3,200,000. Under New York law, the affirmative vote of the holders of
securities representing a majority of the voting power present in person or
represented by proxy at the Meeting is required to adopt the proposed amendment
of the 1991 Plan of the Corporation.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE ADOPTION OF THE AMENDMENT
OF THE 1991 STOCK OPTION PLAN.
3. RESTATEMENT OF THE FORMULA STOCK OPTION PLAN FOR NONEMPLOYEE DIRECTORS
INCREASE IN NUMBER OF OPTIONS AUTOMATICALLY GRANTED TO NONEMPLOYEE DIRECTORS
Directors do not receive cash compensation for attendance at Board of
Directors' meetings or committee meetings. Non-qualified stock options are
awarded to nonemployee directors of the Corporation pursuant to the Formula
Stock Option Plan for Nonemployee Directors (the "Directors' Formula Option
Plan") under and subject to the Corporation's 1991 Plan. There are six
nonemployee directors eligible to receive options under the Directors' Formula
Option Plan. The options have a term of ten years from the date of grant and
are exercisable at a price per share equal to the fair market value of a share
of Common Stock on the date of grant. The amendment and restatement of the
Director's Formula Option Plan will (i) increase the annual option grant to
nonemployee directors from 3,500 shares to 7,500 shares, beginning upon the
third annual meeting instead of the fourth annual meeting, and (ii) allow the
options to be granted under any non-qualified stock option plans of the
Corporation.
The formula for awarding options to nonemployee directors under the
existing Directors' Formula Option Plan is as follows: each person who was a
nonemployee director of the Corporation in November 1992 and served as a
director for two or more years, upon each annual meeting ("Annual Meeting") that
such person remains a nonemployee director, shall automatically be granted an
option to acquire 3,500 shares of Common Stock; each person who was a
nonemployee director of the Corporation in November 1992 and served as a
director for less than two years prior thereto, upon the fourth Annual Meeting
following his or her initial election and each Annual Meeting thereafter that
such person remains a nonemployee director, shall automatically be granted an
option to acquire 3,500 shares of Common Stock; and each person who first
becomes a nonemployee director of the Corporation after November 1992 (i) upon
his or her initial election, shall automatically be granted an option to acquire
25,000 shares of Common Stock which shall be exercisable in four installments of
6,250 shares each with the first installment being at his or her initial
election and the remaining installments becoming exercisable on the date of each
Annual Meeting thereafter that such person is a director, until fully
exercisable, and (ii) upon the fourth Annual Meeting following his or her
initial election and each Annual Meeting thereafter that such person remains a
nonemployee director, shall automatically be granted an option to acquire 3,500
shares of Common Stock. Except as otherwise described above, all such options
are immediately exercisable in full on the date of grant.
On September 1, 1995, the Board amended and restated the Directors' Formula
Option Plan, subject to shareholder approval, as follows: Any nonemployee
director shall (i) upon his or her initial election to the Board of Directors of
the Corporation be granted an option for 25,000 shares of Common Stock which
shall be exercisable in four annual installments of 6,250 shares each with the
first installment being at his or her initial election and the remaining
installments becoming exercisable on the date of each Annual Meeting thereafter
that such person is a director, until fully exercisable, and (ii) upon the third
Annual Meeting following his or her initial election and at each Annual Meeting
thereafter that such person remains a nonemployee director, automatically be
granted an option to acquire 7,500 shares of Common Stock. Except as otherwise
descibed above, all options are immediately exercisable in full on the date of
grant. Options granted to nonemployee directors shall have a term of ten (10)
years from the date of issuance, are granted at exercise prices equal to the
fair market value on the date of grant, and shall be granted under and subject
to the 1991 Plan, except that any provision which is in the discretion of the
Plan Administrator under the 1991 Plan shall not apply to options granted to
nonemployee directors pursuant to the Directors' Formula Option Plan. The
Directors' Formula Option Plan may not be amended more than once every six
months, other than to comport with changes in the Internal Revenue Code of the
Employee Retirement Income Security Act, or the rules thereunder.
<PAGE>
The Board's determination followed consideration of Board compensation by
the Compensation Committee and the entire Board of Directors, which reviewed the
compensation of the board of directors of other biotechnology/pharmaceutical
development companies of a similar size and stage of development. Based on its
review and on the fact that the Corporation's Board does not receive cash
compensation, the Compensation Committee determined that the stock option
compensation was inadequate by the above-mentioned measure.
The following chart sets forth the number of shares subject to options that
will be received by all current directors who are not executive officers as a
group (as of August 31, 1995) for fiscal year 1995, if the Directors' Formula
Option Plan as proposed to be amended is approved:
NEW PLAN BENEFITS
Directors' Formula Stock
Option Plan
Name and Position Number of Shares
----------------- ----------------
Non-Executive Director Group (6
persons)(1)........................................... 45,000(1)
- - -----------
(1) The group includes Carroll O. Johnson, Stephen M. McGrath, Donald E.
O'Neill, Helen M. Ranney, Jean G. Riess, and Thomas F. Zuck.
All current directors who are not executive officers, as a group, have
received options to purchase 99,000 shares of Common Stock under the Directors'
Formula Option Plan as currently in effect. Each nominee for election as a
director has received options to purchase shares of Common Stock under the
Directors' Formula Option Plan, as follows: Carroll O. Johnson, 10,500 shares;
Stephen M. McGrath, 10,500 shares; Donald E. O'Neill, 28,500 shares; Helen M.
Ranney, 28,500 shares; Jean G. Riess, 10,500 shares; and Thomas F. Zuck 10,500
shares.
Shareholders are requested in this Proposal 3 to approve the amendment and
restatement of the Directors' Formula Option Plan. Under New York law, the
affirmative vote of the holders of securities representing the majority of the
voting power present in person or represented by proxy at the meeting is
required to adopt the proposed amendment and restatement of the Directors'
Formula Option Plan.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE AMENDMENT AND RESTATEMENT
OF THE FORMULA STOCK OPTION PLAN FOR NONEMPLOYEE DIRECTORS.
4. RATIFICATION OF APPOINTMENT OF INDEPENDENT AUDITORS
In February 1994, the Audit Committee of the Board of Directors of the
Corporation and the Board of Directors approved a change in the Corporation's
independent auditors. On February 16, 1994, the Corporation dismissed the firm
of Deloitte & Touche LLP as its auditors and engaged Ernst & Young LLP as its
independent auditors for the fiscal year ended June 30, 1994 to replace Deloitte
& Touche.
The reports of Deloitte & Touche on the Corporation's consolidated
financial statements for the fiscal years ended June 30, 1993 did not contain an
adverse opinion or a disclaimer of opinion nor were they qualified or modified
as to uncertainty, audit scope or accounting principles.
In connection with the audits of the Corporation's consolidated financial
statements for each of the years in the period ended June 30, 1993, and during
any subsequent interim period, there were no disagreements with Deloitte &
Touche on any matters of accounting principles or practices, financial statement
disclosure, or auditing scope and procedures, which, if not resolved to the
satisfaction of Deloitte & Touche, would have caused Deloitte & Touche to make
reference to the matter in their reports.
The Board of Directors has selected the accounting firm of Ernst & Young to
serve as the independent auditors for the Corporation for the fiscal year ending
June 30, 1996. Representatives of Ernst & Young are expected to be
<PAGE>
present at the Meeting, will have the opportunity to make a statement if they
desire to do so, and will be available to respond to appropriate questions.
Shareholder ratification of the appointment of Ernst & Young as the
Corporation's independent auditors is not required by the Corporation's Bylaws
or otherwise. If the shareholders fail to ratify the appointment, the Board
will reconsider whether or not to retain that firm. Even if the appointment is
ratified, the Board in its discretion may direct the appointment of a different
independent accounting firm at any time during the year if the Board determines
that such a change would be in the best interests of the Corporation and its
shareholders.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE RATIFICATION OF THE
APPOINTMENT OF ERNST & YOUNG LLP AS INDEPENDENT AUDITORS.
5. OTHER BUSINESS
Management knows of no other matters that may be presented to the Meeting.
However, if any other matter properly comes before the Meeting, it is intended
that proxies in the accompanying form will be voted in accordance with the
judgment of the persons named therein.
FUTURE PROPOSALS BY SHAREHOLDERS
Any proposal which a shareholder of the Corporation wishes to have included
in the proxy statement and proxy relating to the Corporation's 1996 Annual
Meeting pursuant to the provisions of Rule 14a-8 under the Securities Exchange
Act of 1934 must be received by the Corporation at its executive offices no
later than June 15, 1996, and must otherwise comply with the requirements of
Rule 14a-8. The address of the Corporation's executive office is 3040 Science
Park Road, San Diego, CA 92121.
ANNUAL REPORT ON FORM 10-K
THE CORPORATION WILL FURNISH, WITHOUT CHARGE, A COPY OF ITS MOST RECENT
ANNUAL REPORT TO THE SECURITIES AND EXCHANGE COMMISSION ON FORM 10-K, INCLUDING
THE FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES, TO EACH PERSON
SOLICITED HEREUNDER WHO MAILS A WRITTEN REQUEST THEREFOR TO ALLIANCE
PHARMACEUTICAL CORP., 3040 SCIENCE PARK ROAD, SAN DIEGO, CA 92121, ATTENTION:
THEODORE D. ROTH, EXECUTIVE VICE PRESIDENT. THE CORPORATION WILL ALSO FURNISH,
UPON THE PAYMENT OF A REASONABLE FEE TO COVER REPRODUCTION AND MAILING EXPENSES,
A COPY OF ALL EXHIBITS TO SUCH ANNUAL REPORT ON FORM 10-K.
It is important that your shares be represented at the Meeting. If you are
unable to be present in person, you are respectfully requested to sign the
enclosed proxy and return it in the enclosed stamped, addressed envelope as
promptly as possible.
By Order of the Board of Directors,
Duane J. Roth, Chairman
Date: October 12, 1995
San Diego, California
<PAGE>
ALLIANCE PHARMACEUTICAL CORP.
PROXY FOR ANNUAL MEETING OF SHAREHOLDERS --- NOVEMBER 16, 1995
The undersigned, revoking any proxy heretofore given, hereby appoints Carroll O.
Johnson, Stephen M. McGrath and Duane J. Roth or any one of them, proxies of the
undersigned with full power of substitution, with respect to all of the shares
of the Common Stock which the undersigned is entitled to vote at the Annual
Meeting of Shareholders of Alliance Pharmaceutical Corp. (the "Corporation") to
be held on November 16, 1995, at the San Diego Marriott La Jolla, 4240 La Jolla
Village Drive, La Jolla, California 92037 at 10:00 a.m., San Diego time, or any
adjournment thereof.
UNLESS A CONTRARY DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED FOR ALL
NOMINEES LISTED FOR ELECTION AS DIRECTORS, FOR AUTHORIZATION OF ADDITIONAL
SHARES OF COMMON STOCK UNDER THE 1991 STOCK OPTION PLAN, FOR AMENDMENT AND
RESTATEMENT OF THE FORMULA STOCK OPTION PLAN FOR NONEMPLOYEE DIRECTORS, AND FOR
RATIFICATION OF ERNST AND YOUNG LLP AS INDEPENDENT AUDITORS FOR THE FISCAL YEAR
ENDING JUNE 30, 1996. If specific instructions are indicated, this Proxy will
be voted in accordance therewith.
In their discretion, the Proxies are authorized to transact such other business
as may properly come before the meeting or any adjournment thereof.
The Board of Directors has proposed all matters to be voted upon and recommends
a vote FOR all nominees for election as directors, FOR authorization of
additional shares under the 1991 Stock Option Plan, FOR amendment and
restatement of the Formula Stock Option Plan for Nonemployee Directors, and FOR
ratification of Ernst and Young LLP as independent auditors for the fiscal year
ending June 30, 1996. Approval of any matter in this proxy is not related to or
conditioned on the approval of any other matter.
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS.
(To be completed and signed on reverse side)
<PAGE>
[X] PLEASE MARK YOUR
VOTES AS IN THIS
EXAMPLE
1. PROPOSAL 1. FOR WITHHELD NOMINEES: Carroll O. Johnson, Stephen M.
ELECTION OF [_] [_] McGrath, Donald E. O'Neill,
DIRECTORS Dr. Helen M. Ranney,
Dr. Jean G. Riess, Duane J. Roth
and Dr. Thomas F. Zuck
For, except vote withheld from the following nominee(s):
- - ------------------------------------------------------
FOR AGAINST ABSTAIN
2. Authorization of Additional Shares of Common Stock [_] [_] [_]
under the 1991 Stock Option Plan.
3. Amendment and Restatement of the Formula Stock [_] [_] [_]
Option Plan for Nonemployee Directors.
4. Ratification of Ernst and Young LLP as independent [_] [_] [_]
auditors.
SIGNATURE(S)_______________________________________________ DATE ___________
NOTE: Please sign exactly as name appears hereon. If the shares are registered
in the names of two or more persons, each should sign. Executors,
administrators, trustees, guardians, attorneys-in-fact, corporate officers,
general partners and other persons acting in a representative capacity should
add their titles.
The above signed hereby acknowledges receipt of the Notice of Annual Meeting of
Shareholders and the Proxy Statement furnished herewith. PLEASE FILL IN, DATE,
SIGN AND MAIL THIS PROXY IN THE ENCLOSED POST-PAID RETURN ENVELOPE.
